WASHINGTON DC (December 10, 2019) – Today’s agreement reached by the Congressional Trade Working Group and the Trump administration represents a victory for patients.
The revised text creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries. The improved pharmaceutical provisions create the balance between access to medicines and support for innovation that was included in bipartisan 2015 Trade Promotion Authority legislation.
AAM is pleased that Congress and the Administration have made changes to USMCA that support open markets, greater competition and improved cost savings for patients and the three health care systems.
Attribute to: Chester "Chip" Davis, Jr., AAM President and CEO
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.